Table 1.
Demographic and clinical characteristics of patients included in this study.
| Group | Characteristic | Discovery phase | p-value | Training phase | p-value | Validation phase | p-value | Blinded phase | p-value |
|---|---|---|---|---|---|---|---|---|---|
| INRs | n | 7 | 41 | 42 | 20 | ||||
| Male, n (%) | 7(100) | >0.999 | 41 (100) | 0.550 | 39 (93) | 0.973 | 20 (100) | 0.106 | |
| Age, median (IQR) | 27(25–38) | 0.269 | 32 (26–39) | 0.845 | 30 (25–41) | 0.632 | 29 (26–40) | 0.180 | |
| Han ethnic, n (%) | 6 (86) | 0.515 | 36 (88) | 0.478 | 37 (88) | 0.337 | 17 (85) | 0.316 | |
| Subtype CRF01AE, n (%) | 6 (86) | >0.999 | 27 (66) | 0.448 | 26 (62) | 0.976 | 13 (65) | 0.333 | |
| Baseline CD4 (cells/μL), median (IQR) | 316 (295–447) | 0.068 | 329 (282–409) | 0.235 | 330 (271–403) | 0.302 | 297 (245–375) | 0.682 | |
| ART CD4 (cells/μL), median (IQR) | 341 (293–402) | 0.004 | 336 (282–402) | <0.001 | 335 (261–392) | <0.001 | 324 (256–384) | <0.001 | |
| Viral load (log copies/mL), median (IQR) | 4.57 (4.39–4.77) | 0.383 | 4.37 (3.92–4.67) | 0.081 | 4.24 (3.74–4.53) | 0.067 | 4.23 (3.53–4.66) | 0.424 | |
| IRs | n | 7 | 85 | 86 | 19 | ||||
| Male, n (%) | 7 (100) | 82 (96) | 80 (93) | 16 (84) | |||||
| Age, median (IQR) | 35 (29–41) | 31 (27–40) | 30 (25–42) | 32 (27–49) | |||||
| Han ethnicity, n (%) | 5 (71) | 78 (92) | 70 (81) | 18 (95) | |||||
| Subtype CRF01AE, n (%) | 6 (86) | 50 (59) | 53 (62) | 15 (79) | |||||
| Baseline CD4 (cells/μL), median (IQR) | 249 (217–397) | 310 (266–350) | 315 (279–350) | 303 (269–343) | |||||
| ART CD4 (cells/μL), median (IQR) | 590 (476–815) | 526 (450–639) | 574 (476–629) | 509 (414–675) | |||||
| Viral load (log copies/mL), median (IQR) | 4.38 (3.98–4.94) | 4.55 (4.11–4.93) | 4.47 (3.89–4.77) | 4.36 (3.98–4.77) |
ART, antiretroviral therapy; INRs, immunological non-responders; IRs, immunological responders; IQR, interquartile range; n, number. p-value: INRs compared with IRs.